1. Home
  2. OMER vs HFFG Comparison

OMER vs HFFG Comparison

Compare OMER & HFFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • HFFG
  • Stock Information
  • Founded
  • OMER 1994
  • HFFG 1997
  • Country
  • OMER United States
  • HFFG United States
  • Employees
  • OMER N/A
  • HFFG N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • HFFG Food Distributors
  • Sector
  • OMER Health Care
  • HFFG Consumer Discretionary
  • Exchange
  • OMER Nasdaq
  • HFFG Nasdaq
  • Market Cap
  • OMER 188.1M
  • HFFG 208.3M
  • IPO Year
  • OMER 2009
  • HFFG N/A
  • Fundamental
  • Price
  • OMER $4.02
  • HFFG $2.90
  • Analyst Decision
  • OMER Strong Buy
  • HFFG
  • Analyst Count
  • OMER 5
  • HFFG 0
  • Target Price
  • OMER $18.00
  • HFFG N/A
  • AVG Volume (30 Days)
  • OMER 1.5M
  • HFFG 67.0K
  • Earning Date
  • OMER 08-15-2025
  • HFFG 08-11-2025
  • Dividend Yield
  • OMER N/A
  • HFFG N/A
  • EPS Growth
  • OMER N/A
  • HFFG N/A
  • EPS
  • OMER N/A
  • HFFG N/A
  • Revenue
  • OMER N/A
  • HFFG $1,204,441,000.00
  • Revenue This Year
  • OMER N/A
  • HFFG $4.27
  • Revenue Next Year
  • OMER $3,416.31
  • HFFG $4.47
  • P/E Ratio
  • OMER N/A
  • HFFG N/A
  • Revenue Growth
  • OMER N/A
  • HFFG 4.71
  • 52 Week Low
  • OMER $2.95
  • HFFG $1.70
  • 52 Week High
  • OMER $13.60
  • HFFG $4.93
  • Technical
  • Relative Strength Index (RSI)
  • OMER 57.36
  • HFFG 41.59
  • Support Level
  • OMER $3.44
  • HFFG $2.58
  • Resistance Level
  • OMER $4.52
  • HFFG $3.07
  • Average True Range (ATR)
  • OMER 0.38
  • HFFG 0.17
  • MACD
  • OMER 0.03
  • HFFG -0.01
  • Stochastic Oscillator
  • OMER 57.63
  • HFFG 39.51

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About HFFG HF Foods Group Inc.

HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, seafood, frozen and dry food, and non-food products to Asian restaurants and other food service customers throughout the United States. The company's business consists of one operating segment; HF Group, which operates solely in the United States. The company's customer base consists of Chinese and Asian restaurants, and it provides sales and service support to customers who mainly converse in Mandarin or Chinese dialects.

Share on Social Networks: